特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

核医学/放射性医薬品市場:動向、予測、競合分析

Nuclear Medicine/Radiopharmaceutical Market Report: Trends, Forecast and Competitive Analysis

発行 Lucintel - Semi-Custom Reports 商品コード 944276
出版日 ページ情報 英文
納期: 約3~5週間
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。

【セミカスタムオーダー型の調査レポート】
当レポートは、目次内の調査項目について *追加/変更ご要望を反映させる事も可能です。
ご注文を承った時点からLucintel社データベースより最新のデータを抽出・分析・編集を行うため、納品には約3~5週間程度を要します。
* ご要望が無い場合は目次通りの内容構成にて作成となります。
* ご要望項目の分量によりましては追加費用が発生する場合がございます。

核医学/放射性医薬品市場:動向、予測、競合分析 Nuclear Medicine/Radiopharmaceutical Market Report: Trends, Forecast and Competitive Analysis
出版日: 2020年06月01日 ページ情報: 英文
概要

世界の核医学/放射性医薬品市場の将来は、病院・診断センター、研究機関における機会が有力です。世界の核医学/放射性医薬品市場は、2019年~2024年のCAGRで9%の成長が予測されています。市場の主要な促進要因として、がん・心血管疾患(CVD)の発生率と有病率の増加、官民パートナーシップを通じた投資の拡大などが挙げられます。

当レポートでは、世界の核医学/放射性医薬品市場について調査分析し、市場動向と予測分析、競合分析、成長機会と戦略的分析、主要企業などについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の背景と分類

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 市場動向と予測分析

  • マクロ経済の動向と予測
  • 世界の核医学/放射性医薬品市場:動向と予測
  • 世界の核医学/放射性医薬品市場:製品タイプ別
    • 核医学診断/放射性医薬品
    • 核医学治療/放射性医薬品
  • 世界の核医学/放射性医薬品市場:適応別
    • 心臓病
    • リンパ腫
    • 甲状腺
    • 神経
    • 腫瘍
    • 骨転移
    • 内分泌腫瘍
  • 世界の核医学/放射性医薬品市場:最終用途業界別
    • 病院・診断センター
    • 研究機関

第4章 市場動向と予測分析:地域別

  • 世界の核医学/放射性医薬品市場:地域別
  • 北米の核医学/放射性医薬品市場
  • 欧州の核医学/放射性医薬品市場
  • アジア太平洋地域の核医学/放射性医薬品市場
  • その他の地域の核医学/放射性医薬品市場

第5章 競合企業の分析

  • 製品ポートフォリオ分析
  • 市場シェア分析
  • 経営統合
  • 地理的範囲
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
  • 世界の核医学/放射性医薬品市場における新興動向
  • 戦略的分析

第7章 主要企業プロファイル

  • Cardinal Health
  • Mallinckrodt
  • GE Healthcare
  • Lantheus Medical Imaging
  • Bayer
  • Bracco Imaging
  • Eczacibasi-Monrol Nuclear Products
  • Noridion
  • IBA Molecular
目次

The future of the nuclear medicine/radiopharmaceutical market looks promising with opportunities in the hospitals, diagnostic centers, and research institutes. The global nuclear medicine/radiopharmaceutical market is expected to grow with a CAGR of 9% from 2019 to 2024. The major drivers for this market are increasing incidence and prevalence of cancer and cardiovascular diseases (CVD) and growing investment through public private partnerships to modernize diagnostic imaging centers, alpha radioimmunotherapy (RIT) based targeted cancer treatment, and advances in radiotracers.

A report of more than 150-pages is developed to help in your business decisions. Sample figures with some insights are shown below. To learn the scope of, benefits, companies researched and other details of nuclear medicine/radiopharmaceuticals market report download the report brochure.

The study includes the nuclear medicine/radiopharmaceutical market size and forecast for the global nuclear medicine/radiopharmaceutical market through 2024, segmented by product type, application, end user, and region as follows:

By Product Type [$M shipment analysis for 2013 - 2024]:

  • Diagnostic Nuclear Medicine/Radiopharmaceutical
    • SPECT Radiopharmaceutical
    • PET Radiopharmaceutical
  • Therapeutic Nuclear Medicine/Radiopharmaceutical
    • Beta Emitters
    • Alpha Emitters
    • Brachytherapy

By Application [$M shipment analysis for 2013 - 2024]:

  • Cardiology
  • Lymphoma
  • Thyroid
  • Neurology
  • Oncology
  • Bone Metastasis
  • Endocrine Tumors

By End User [$M shipment analysis for 2013 - 2024]:

  • Hospitals and Diagnostic Centers
  • Research Institutes

By Region [$M shipment analysis for 2013 - 2024]:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
  • Rest of the World (ROW)
    • Brazil

Some of the nuclear medicine/radiopharmaceutical companies profiled in this report include Cardinal Health, Mallinckrodt, GE Healthcare, Lantheus Medical Imaging, Bayer, Bracco Imaging, Eczacibasi-Monrol Nuclear Products, Noridian, and Iba Molecular.

Some of the features of "Global Nuclear Medicine/Radiopharmaceuticals Market 2019-2024: Trends, Forecast, and Opportunity Analysis" include

  • Market size estimates:Global nuclear medicine/radiopharmaceuticals market size estimation in terms of value ($M) shipment.
  • Trend and forecast analysis:Market trend (2013-2018) and forecast (2019-2024) by segments and region.
  • Segmentation analysis:Global market size by various applications such as by product type, application, end user, and region.
  • Regional analysis:Global nuclear medicine/radiopharmaceuticals market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
  • Growth opportunities:Analysis on growth opportunities in different applications and regions for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
  • Strategic analysis:This includes M&A, new product development, and competitive landscape for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising potential, high-growth opportunities for the global nuclear medicine/radiopharmaceutical market by product type (diagnostic nuclear medicine/radiopharmaceutical (SPECT radiopharmaceutical, PET radiopharmaceutical), and therapeutic nuclear medicine/radiopharmaceutical (beta emitters, alpha emitters and brachytherapy), application (Cardiology, lymphoma, thyroid, oncology, neurology, bone metastasis, endocrine tumors), end user (hospitals and diagnostic centers, and research institutes), and region (North America, Asia-Pacific, Europe, Rest of the World(ROW))?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which regions will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the drivers and challenges of the nuclear medicine/radiopharmaceutical market?
  • Q.5. What are the business risks and threats to the nuclear medicine/radiopharmaceutical market?
  • Q.6. What are emerging trends in this nuclear medicine/radiopharmaceutical market and the reasons behind them?
  • Q.7. What are some changing demands of customers in the nuclear medicine/radiopharmaceutical market?
  • Q.8. What are the new developments in the nuclear medicine/radiopharmaceutical market? Which companies are leading these developments?
  • Q.9. Who are the major players in this nuclear medicine/radiopharmaceutical market? What strategic initiatives are being implemented by key players for business growth?
  • Q.10. What are some of the competitive products and processes in this nuclear medicine/radiopharmaceutical area and how big of a threat do they pose for loss of market share via material or product substitution?
  • Q.11. What M&A activities have taken place in the last 5 years in this nuclear medicine/radiopharmaceutical market?

1. Executive Summary

2. Market Background and Classifications

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2013 to 2024

  • 3.1: Macroeconomic Trends and Forecast
  • 3.2: Global Nuclear Medicine/Radiopharmaceuticals Market: Trends and Forecast
  • 3.3: Global Nuclear Medicine/Radiopharmaceuticals Market by Product Type
    • 3.3.1: Diagnostic Nuclear Medicine / Radiopharmaceutical
      • 3.3.1.1: SPECT Radiopharmaceutical
      • 3.3.1.2: PET Radiopharmaceutical
    • 3.3.2: Therapeutic Nuclear Medicine/Radiopharmaceutical
      • 3.3.2.1: Beta Emitters
      • 3.3.2.2: Alpha Emitters
      • 3.3.2.3: Brachytherapy
  • 3.4: Global Nuclear Medicine/Radiopharmaceuticals Market by Application
    • 3.4.1: Cardiology
    • 3.4.2: Lymphoma
    • 3.4.3: Thyroid
    • 3.4.4: Neurology
    • 3.4.5: Oncology
    • 3.4.6: Bone Metastasis
    • 3.4.7: Endocrine Tumors
  • 3.5: Global Nuclear Medicine/Radiopharmaceuticals Market by End Use Industry
    • 3.5.1: Hospitals and Diagnostic Centers
    • 3.5.2: Research Institutes

4. Market Trends and Forecast Analysis by Region

  • 4.1: Global Nuclear Medicine/Radiopharmaceuticals Market by Region
  • 4.2: North American Nuclear Medicine/Radiopharmaceuticals Market
    • 4.2.1: Market by End Use Industry: Hospitals and Diagnostic Centers, and Research Institutes
  • 4.3: European Nuclear Medicine/Radiopharmaceuticals Market
    • 4.3.1: Market by End Use Industry: Hospitals and Diagnostic Centers, and Research Institutes
  • 4.4: APAC Nuclear Medicine/Radiopharmaceuticals Market
    • 4.4.1: Hospitals and Diagnostic Centers, and Research Institutes
  • 4.5: ROW Nuclear Medicine/Radiopharmaceuticals Market
    • 4.5.1: Hospitals and Diagnostic Centers, and Research Institutes

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Market Share Analysis
  • 5.3: Operational Integration
  • 5.4: Geographical Reach
  • 5.5: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by Product Type
    • 6.1.2: Growth Opportunities for Global Market by Application
    • 6.1.3: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by End Use Industry
    • 6.1.4: Growth Opportunities for Global Nuclear Medicine/Radiopharmaceuticals Market by Region
  • 6.2: Emerging Trends in Global Nuclear Medicine/Radiopharmaceuticals Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of Global Nuclear Medicine/Radiopharmaceuticals Market
    • 6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Market

7. Company Profiles of Leading Players

  • 7.1: Cardinal Health
  • 7.2: Mallinckrodt
  • 7.3: GE Healthcare
  • 7.4: Lantheus Medical Imaging
  • 7.5: Bayer
  • 7.6: Bracco Imaging
  • 7.7: Eczacibasi-Monrol Nuclear Products
  • 7.8: Noridion
  • 7.9: IBA Molecular